Target Price | $39.06 |
Price | $34.41 |
Potential | 13.51% |
Number of Estimates | 17 |
17 Analysts have issued a price target Keurig Dr Pepper Inc 2026 . The average Keurig Dr Pepper Inc target price is $39.06. This is 13.51% higher than the current stock price. The highest price target is $42.00 22.06% , the lowest is $34.00 1.19% . | |
A rating was issued by 22 analysts: 14 Analysts recommend Keurig Dr Pepper Inc to buy, 8 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Keurig Dr Pepper Inc stock has an average upside potential 2026 of 13.51% . Most analysts recommend the Keurig Dr Pepper Inc stock at Purchase. |
15 Analysts have issued a sales forecast Keurig Dr Pepper Inc 2025 . The average Keurig Dr Pepper Inc sales estimate is $16.2b . This is 4.22% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $16.4b 5.63% , the lowest is $16.0b 3.02% .
This results in the following potential growth metrics:
2024 | $15.4b | 3.62% |
---|---|---|
2025 | $16.2b | 5.35% |
2026 | $16.8b | 3.99% |
2027 | $17.4b | 3.63% |
2028 | $17.9b | 2.44% |
12 Analysts have issued an Keurig Dr Pepper Inc EBITDA forecast 2025. The average Keurig Dr Pepper Inc EBITDA estimate is $4.8b . This is 11.88% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $5.0b 15.59% , the lowest is $4.4b 2.85% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $4.3b | 9.68% |
---|---|---|
2025 | $4.8b | 11.73% |
2026 | $5.1b | 5.02% |
2027 | $5.3b | 4.61% |
2028 | $5.3b | 0.78% |
2024 | 28.04% | 5.84% |
---|---|---|
2025 | 29.74% | 6.05% |
2026 | 30.03% | 0.98% |
2027 | 30.32% | 0.97% |
2028 | 29.82% | 1.65% |
6 Keurig Dr Pepper Inc Analysts have issued a net profit forecast 2025. The average Keurig Dr Pepper Inc net profit estimate is $2.7b . This is 78.33% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $2.8b 87.27% , the lowest is $2.5b 66.36% .
This results in the following potential growth metrics and future Net Margins:
2024 | $1.4b | 32.26% |
---|---|---|
2025 | $2.7b | 86.83% |
2026 | $2.8b | 6.88% |
2027 | $3.0b | 4.55% |
2028 | $3.4b | 13.16% |
2024 | 9.29% | 34.63% |
---|---|---|
2025 | 16.47% | 77.29% |
2026 | 16.93% | 2.79% |
2027 | 17.08% | 0.89% |
2028 | 18.87% | 10.48% |
6 Analysts have issued a Keurig Dr Pepper Inc forecast for earnings per share. The average Keurig Dr Pepper Inc EPS is $1.96 . This is 78.18% higher than earnings per share in the financial year 2024. The highest EPS forecast is $2.06 87.27% , the lowest is $1.83 66.36% .
This results in the following potential growth metrics and future valuations:
2024 | $1.05 | 32.26% |
---|---|---|
2025 | $1.96 | 86.67% |
2026 | $2.10 | 7.14% |
2027 | $2.19 | 4.29% |
2028 | $2.48 | 13.24% |
Current | 31.17 | 42.98% |
---|---|---|
2025 | 17.54 | 43.73% |
2026 | 16.41 | 6.44% |
2027 | 15.70 | 4.33% |
2028 | 13.87 | 11.66% |
Based on analysts' sales estimates for 2025, the Keurig Dr Pepper Inc stock is valued at an EV/Sales of 3.94 and an P/S ratio of 2.89 .
This results in the following potential growth metrics and future valuations:
Current | 4.10 | 2.84% |
---|---|---|
2025 | 3.94 | 3.98% |
2026 | 3.79 | 3.84% |
2027 | 3.65 | 3.51% |
2028 | 3.57 | 2.38% |
Current | 3.01 | 3.91% |
---|---|---|
2025 | 2.89 | 4.05% |
2026 | 2.78 | 3.84% |
2027 | 2.68 | 3.51% |
2028 | 2.62 | 2.39% |
Keurig Dr Pepper Inc...
Analyst | Rating | Action | Date |
---|---|---|---|
Barclays |
Overweight
➜
Overweight
|
Unchanged | Apr 28 2025 |
HSBC |
Hold
➜
Buy
|
Upgrade | Apr 25 2025 |
RBC Capital |
Outperform
➜
Outperform
|
Unchanged | Apr 22 2025 |
UBS |
Buy
➜
Buy
|
Unchanged | Apr 17 2025 |
Argus Research |
➜
Buy
|
Initiated | Apr 16 2025 |
Piper Sandler |
Neutral
➜
Overweight
|
Upgrade | Apr 09 2025 |
Morgan Stanley |
Equal-Weight
➜
Overweight
|
Upgrade | Apr 01 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Barclays:
Overweight
➜
Overweight
|
Apr 28 2025 |
Upgrade
HSBC:
Hold
➜
Buy
|
Apr 25 2025 |
Unchanged
RBC Capital:
Outperform
➜
Outperform
|
Apr 22 2025 |
Unchanged
UBS:
Buy
➜
Buy
|
Apr 17 2025 |
Initiated
Argus Research:
➜
Buy
|
Apr 16 2025 |
Upgrade
Piper Sandler:
Neutral
➜
Overweight
|
Apr 09 2025 |
Upgrade
Morgan Stanley:
Equal-Weight
➜
Overweight
|
Apr 01 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.